Abbott Laboratories plans to acquire Exact Sciences Corp. (NASDAQ:EXAS) for approximately $21 billion, offering $105 per share.Stifel Nicolaus set a price target of $105 for EXAS, aligning with Abbott's acquisition offer.Exact Sciences reported $851 million in revenue for the third quarter and increased its full-year revenue forecast to between $3.22 billion and $3.235 billion.Exact Sciences Corp. (NASDAQ:EXAS) is a prominent player in the field of cancer screening tests, known for its innovative products l ...